Emerging pathogens: Dynamics, mutation and drug resistance

Perelson, A S; Goldstein, B; Korber, B T

doi:10.2172/534529

Title: Emerging pathogens: Dynamics, mutation and drug resistance

Full Record
Other Related Research

Abstract

This is the final report of a one-year, Laboratory Directed Research and Development (LDRD) project at Los Alamos National Laboratory (LANL). The objectives of this project were to develop models of the spread of pathogens, such as HIV-1 and influenza, in humans, and then to use the models to address the possibility of designing appropriate drug therapies that may limit the ability of the pathogen to escape treatment by mutating into a drug resistant form. We have developed a model of drug-resistance to amantidine and rimantadine, the two major antiviral drugs used to treat influenza, and have used the model to suggest treatment strategies during an epidemic.

Authors:

Perelson, A S; Goldstein, B; Korber, B T ^[1]

and others

Publication Date:: Wed Oct 01 00:00:00 EDT 1997

Research Org.:: Los Alamos National Lab. (LANL), Los Alamos, NM (United States)

Sponsoring Org.:: USDOE Assistant Secretary for Human Resources and Administration, Washington, DC (United States)

OSTI Identifier:: 534529

Report Number(s):: LA-UR-97-3505
ON: DE98000090; TRN: 97:005410

DOE Contract Number:: W-7405-ENG-36

Resource Type:: Technical Report

Resource Relation:: Other Information: PBD: [1997]

Country of Publication:: United States

Language:: English

Subject:: 55 BIOLOGY AND MEDICINE, BASIC STUDIES; PATHOGENS; THERAPY; DRUGS; INFLUENZA; AIDS VIRUS; MUTATIONS; INFECTIOUS DISEASES

Citation Formats


                    Perelson, A S, Goldstein, B, and Korber, B T. Emerging pathogens: Dynamics, mutation and drug resistance.  United States: N. p., 1997. 
        Web.  doi:10.2172/534529.

Copy to clipboard


                    Perelson, A S, Goldstein, B, & Korber, B T. Emerging pathogens: Dynamics, mutation and drug resistance.  United States.  https://doi.org/10.2172/534529

Copy to clipboard


                    Perelson, A S, Goldstein, B, and Korber, B T. 1997.  
        "Emerging pathogens: Dynamics, mutation and drug resistance".  United States.  https://doi.org/10.2172/534529.  https://www.osti.gov/servlets/purl/534529.

Copy to clipboard


                    
@article{osti_534529,

  title        = {Emerging pathogens: Dynamics, mutation and drug resistance},

  author       = {Perelson, A S and Goldstein, B and Korber, B T},

  abstractNote = {This is the final report of a one-year, Laboratory Directed Research and Development (LDRD) project at Los Alamos National Laboratory (LANL). The objectives of this project were to develop models of the spread of pathogens, such as HIV-1 and influenza, in humans, and then to use the models to address the possibility of designing appropriate drug therapies that may limit the ability of the pathogen to escape treatment by mutating into a drug resistant form. We have developed a model of drug-resistance to amantidine and rimantadine, the two major antiviral drugs used to treat influenza, and have used the model to suggest treatment strategies during an epidemic.},

  doi          = {10.2172/534529},

  url          = {https://www.osti.gov/biblio/534529},
  journal      = {},
number       = ,

  volume       = ,

  place        = {United States},

  year         = {Wed Oct 01 00:00:00 EDT 1997},

  month        = {Wed Oct 01 00:00:00 EDT 1997}

}

Copy to clipboard

Technical Report:

View Technical Report (1.30 MB)

https://doi.org/10.2172/534529

Save / Share:

Export Metadata

Save to My Library

Similar records in OSTI.GOV collections:

Structures of HIV Protease Guide Inhibitor Design to Overcome Drug Resistance

Book Weber, Irene; Kovalevsky, Andrey; Harrison, Robert

The HIV/AIDS infection continues to be a major epidemic worldwide despite the initial promise of antiviral drugs. Current therapy includes a combination of drugs that inhibit two of the virally-encoded enzymes, the reverse transcriptase and the protease. The first generation of HIV protease inhibitors that have been in clinical use for treatment of AIDS since 1995 was developed with the aid of structural analysis of protease-inhibitor complexes. These drugs were successful in improving the life span of HIV-infected people. Subsequently, the rapid emergence of drug resistance has necessitated the design of new inhibitors that target mutant proteases. This second generationmore »« less
Substitution of the transmembrane domain of Vpu in simian-human immunodeficiency virus (SHIV{sub KU1bMC33}) with that of M2 of influenza A results in a virus that is sensitive to inhibitors of the M2 ion channel and is pathogenic for pig-tailed macaques

Journal Article Hout, David; Gomez, Melissa; Pacyniak, Erik; ... - Virology

The Vpu protein of human immunodeficiency virus type 1 has been shown to shunt the CD4 receptor molecule to the proteasome for degradation and to enhance virus release from infected cells. The exact mechanism by which the Vpu protein enhances virus release is currently unknown but some investigators have shown that this function is associated with the transmembrane domain and potential ion channel properties. In this study, we determined if the transmembrane domain of Vpu could be functionally substituted with that of the prototypical viroporin, the M2 protein of influenza A virus. We constructed chimeric vpu gene in which themore »« less
https://doi.org/10.1016/J.VIROL.2005.0
Solution NMR structure of the V27A drug resistant mutant of influenza A M2 channel

Journal Article Pielak, Rafal - Biochemical and Biophysical Research Communications

Research highlights: {yields} This paper reports the structure of the V27A drug resistant mutant of the M2 channel of influenza A virus. {yields} High quality NMR data allowed a better-defined structure for the C-terminal region of the M2 channel. {yields} Using the structure, we propose a proton transfer pathway during M2 proton conduction. {yields} Structural comparison between the wildtype, V27A and S31N variants allowed an in-depth analysis of possible modes of drug resistance. {yields} Distinct feature of the V27A channel pore also provides an explanation for its faster rate of proton conduction. -- Abstract: The M2 protein of influenza Amore »« less
https://doi.org/10.1016/J.BBRC.2010.09.008
Triple Combination Antiviral Drug (TCAD) Composed of Amantadine, Oseltamivir, and Ribavirin Impedes the Selection of Drug-Resistant Influenza A Virus

Journal Article Hoopes, Justin; Driebe, Elizabeth; Kelley, Erin; ... - PLoS ONE

Widespread resistance among circulating influenza A strains to at least one of the anti-influenza drugs is a major public health concern. A triple combination antiviral drug (TCAD) regimen comprised of amantadine, oseltamivir, and ribavirin has been shown to have synergistic and broad spectrum activity against influenza A strains, including drug resistant strains. Here, we used mathematical modeling along with three different experimental approaches to understand the effects of single agents, double combinations, and the TCAD regimen on resistance in influenza in vitro, including: 1) serial passage at constant drug concentrations, 2) serial passage at escalating drug concentrations, and 3) evaluationmore »« less
https://doi.org/10.1371/journal.pone.0029778

Full Text Available
Mechanism of Drug Resistance Revealed by the Crystal Structure of the Unliganded HIV-1 Protease with F53L Mutation

Journal Article Liu, Fengling; Kovalevsky, Andrey; Louis, John; ... - J. Mol. Biol.

Mutations in HIV-1 protease (PR) that produce resistance to antiviral PR inhibitors are a major problem in AIDS therapy. The mutation F53L arising from antiretroviral therapy was introduced into the flexible flap region of the wild-type PR to study its effect and potential role in developing drug resistance. Compared to wild-type PR, PR{sub F53L} showed lower (15%) catalytic efficiency, 20-fold weaker inhibition by the clinical drug indinavir, and reduced dimer stability, while the inhibition constants of two peptide analog inhibitors were slightly lower than those for PR. The crystal structure of PR{sub F53L} was determined in the unliganded form atmore »« less
https://doi.org/10.1016/j.jmb.2006.02.076

Similar Records